RxDoctor Payments Data

Derek Yuan, MD

Neurology · Johnson City, NYNPI 1548503642

Payments from drug & device makers

$75,398in general payments, 2019–2025

Across 189 payments — averaging $398.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$52K
  • Pfizer$21K
  • Amgen$378
  • SK Life Science, Inc.$260
  • Lundbeck LLC$172
  • Jazz Pharmaceuticals Inc.$150
  • plus $962 from 25 others

What the payments were for

  • Consulting fees$1,8002%
  • Speaking & faculty fees$68,34691%
  • Food & beverage$5,2387%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,398 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$54,451
Medicare patients
106
Services billed
6,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab26$222,253
Nurtec OdtRimegepant Sulfate86$157,061
UbrelvyUbrogepant63$110,065
Emgality PenGalcanezumab-Gnlm145$106,237
Aimovig AutoinjectorErenumab-Aooe85$70,850
BanzelRufinamide12$53,603
RytaryCarbidopa/Levodopa30$41,347
Ajovy AutoinjectorFremanezumab-Vfrm49$33,930
QuliptaAtogepant26$29,148
Sumatriptan Succinate38$4,724
Levetiracetam71$3,493
Eletriptan HbrEletriptan Hydrobromide32$3,374
Frovatriptan Succinate18$2,762
RizatriptanRizatriptan Benzoate121$2,669
Divalproex Sodium37$2,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$20,982$157,06186 claims
AbbVieUbrelvy, Qulipta$52,495$139,21389 claims
Eisai Inc.Banzel$32$53,60312 claims
Amneal Pharmaceuticals LLCRytary$43$41,34730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →